Liver International

Article	Citations
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD	305
Pathophysiological mechanisms of liver injury in COVID‐19	283
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review	192
Changing epidemiology of hepatocellular carcinoma in Asia	163
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population	150
Hepatic macrophages: Key players in the development and progression of liver fibrosis	92
Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis	91
Diet and exercise in NAFLD/NASH: Beyond the obvious	89
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis	86
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)	81
Hepatitis E: An update on One Health and clinical medicine	79
The changing scenario of hepatocellular carcinoma in Italy: an update	74
The NAFLD‐MAFLD debate: Eminence vs evidence	68
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups	66
Exploring the landscape of steatotic liver disease in the general US population	62
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH	61
Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group	61
Treatment and the prognosis of hepatocellular carcinoma in Asia	59
Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID‐19	59
Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia	57
Incidence and risk factors of drug‐induced liver injury	54
Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China an	53
Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study	53
Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?	51
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	51

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study	50
Clinical characteristics of COVID‐19 patients with hepatitis B virus infection — a retrospective study	49
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease	46
Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study	45
2021 ISHEN guidelines on animal models of hepatic encephalopathy	45
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma	44
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis	43
Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States	42
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	41
Safety of direct oral anticoagulants in patients with advanced liver disease	41
Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives	40
Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?	40
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis	40
Management of NAFLD in primary care settings	39
Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease	39
Association of genetic variations with NAFLD in lean individuals	39
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…	39
Association of gut microbiome and primary liver cancer: A two‐sample Mendelian randomization and case–control study	38
New drugs for NASH	38
Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study	38
Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury	37
HBV 2021: New therapeutic strategies against an old foe	37
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry	37
Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI	37
Safety and antibody response to inactivated COVID‐19 vaccine in patients with chronic hepatitis B virus infection	36
Rodent models of cholestatic liver disease: A practical guide for translational research	36
Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients	36
Liver involvement in children with SARS‐COV‐2 infection: Two distinct clinical phenotypes caused by the same virus	36
Integrins as a drug target in liver fibrosis	36
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life	36
Role of fibroblast growth factor signalling in hepatic fibrosis	36
Factors associated with health‐related quality of life in patients with cirrhosis: a systematic review	35
Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip	35
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure	34
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data	34
COVID‐19 and the liver: A 2021 update	34
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease	33
The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria	32
The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt	32
Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure: A propensity‐score matched study from AARC	32
From NAFLD to MAFLD: Nurse and allied health perspective	32
Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high‐risk patients	32
Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma	31
Nationwide treatment and outcomes of perihilar cholangiocarcinoma	31
The association of sex steroid hormone concentrations with non‐alcoholic fatty liver disease and liver enzymes in US men	31
Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan	31
Coordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipients	31
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis	31
Interferon‐based treatment of chronic hepatitis D	30
Effects of two personalized dietary strategies during a 2‐year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial	30

Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation	30
Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes	30
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	30
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia	30
Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension	29
Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection	29
PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD	29
Road to elimination of HCV: Clinical challenges in HCV management	29
Machine‐learning radiomics to predict early recurrence in perihilar cholangiocarcinoma after curative resection	29
Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial	29
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	29
Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use	28
Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD	28
Hepatocyte‐derived MANF alleviates hepatic ischaemia‐reperfusion injury via regulating endoplasmic reticulum stress‐induced apoptosis in mice	28
The role of hepatic lipid composition in obesity‐related metabolic disease	28
Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis: A cohort study	28
Bariatric surgery and the risk of alcohol‐related cirrhosis and alcohol misuse	28
Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma	28
Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar	27
Liver transplantation in patients with liver failure: Twenty years of experience from China	27
Safety of fibrates in cholestatic liver diseases	26
Deep learning for noninvasive liver fibrosis classification: A systematic review	26
A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis	26
Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens	26
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	26
HCC advances in diagnosis and prognosis: Digital and Imaging	26
Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids	26
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab	26
Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis	25
Chanarin‐Dorfman Syndrome: A comprehensive review	25
Association between non‐alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study	25
Epidemiological projections of viral‐induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination	25
Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis	25
Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study	24
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma	24
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)	24
Liver transplantation for acute‐on‐chronic liver failure predicts post‐transplant mortality and impaired long‐term quality of life	24
Cellular senescence and hepatitis B‐related hepatocellular carcinoma: An intriguing link	24
Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance	24
Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta‐analysis	24
Contribution of a genetic risk score to ethnic differences in fatty liver disease	23
Paradigm shift in the treatment options of hepatocellular carcinoma	23
Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease	23
The association of the steatosis severity in fatty liver disease with coronary plaque pattern in general population	23
Epidemiology and surveillance of autoimmune hepatitis in Asia	23
COVID‐19 and the liver – Lessons learned	23
Impact on follow‐up strategies in patients with primary sclerosing cholangitis	23
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis	23
High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma	22
Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications	22
Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients	22
YAP‐induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer	22
A population‐based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007‐2017	22
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis	22
Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies	22
Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes	22
m5C and m6A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR‐582‐3p‐YAP1 axis	22
Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population‐based study	22
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice	21
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B	21
Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles	21
One size does not fit all; practical, personal tailoring of the diet to NAFLD patients	21
Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort	21
Metabolic‐associated fatty liver disease (MAFLD) in coeliac disease	21
Non‐selective beta‐blockers in patients with ascites: The complex interplay among the liver, kidney and heart	21
A typical autoimmune hepatitis (AIH) case following Covid‐19 mRNA vaccination. More than a coincidence?	21
Pregnancy outcome of anti‐HCV direct‐acting antivirals: Real‐life data from an Egyptian cohort	21
Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults	21
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	21
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects	21
SPARC inhibition accelerates NAFLD‐associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism	21
Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis	20
Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study	20
Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population‐based study	20
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension	20
Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment	20
Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma	20
Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis	20
The global trends and regional differences in incidence of HEV infection from 1990 to 2017 and implications for HEV prevention	20
New therapies for hepatitis delta virus infection	19

Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review	19
Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease	19
Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea	19
Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up	19
Liver regeneration: Cellular origin and molecular mechanisms	19
Natural history of NASH	19
Exosome‐derived differentiation antagonizing non‐protein coding RNA with risk of hepatitis C virus‐related hepatocellular carcinoma recurrence	19
Changing clinical management of NAFLD in Asia	19
Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis	19
Sarco‐Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation	18
Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol‐related cirrhosis	18
Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease	18
Roles for the mycobiome in liver disease	18
Estrogens in polycystic liver disease: A target for future therapies?	18
A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity	18
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma	18
Long non‐coding RNA H19 as a biomarker for hepatocellular carcinoma	18
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	18
Causal relationships between metabolic‐associated fatty liver disease and iron status: Two‐sample Mendelian randomization	18
Implication of CD69+CD103+ tissue‐resident‐like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma	18
Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course	18
Changes in therapeutic options for hepatocellular carcinoma in Asia	18
Co‐expression of IL‐7 and PH20 promote anti‐GPC3 CAR‐T tumour suppressor activity in vivo and in vitro	18
A history of variceal bleeding is associated with further bleeding under atezolizumab–bevacizumab in patients with HCC	18
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib	18
LGR5 induces β‐catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma	18
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	18
Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents	18
Hepatology in space: Effects of spaceflight and simulated microgravity on the liver	18
Adherence to the dietary approaches to stop hypertension diet and non‐alcoholic fatty liver disease	18
Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study	17
Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy‐proven non‐alcoholic fatty liver disease	17
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements	17
Immunogenicity of COVID‐19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta‐analysis	17
Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta‐analysis	17
Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia	17
Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review	17
The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma	17
The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries	17
Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta‐analysis	17
Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients	17
ABI2‐mediated MEOX2/KLF4‐NANOG axis promotes liver cancer stem cell and drives tumour recurrence	16
Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset	16
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis	16
The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?	16
The crosstalk network of XIST/miR‐424‐5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer	16
The impact of fatigue on mortality of patients with non‐alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005–2010 and 2017–2018	16
The first MASH drug therapy on the horizon: Current perspectives of resmetirom	16
Using MR elastography to assess portal hypertension and response to beta‐blockers in patients with cirrhosis	16
Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy	16
The relationship between frailty and cirrhosis etiology: From the Functional Assessment in Liver Transplantation (FrAILT) Study	16
Current management of NAFLD/NASH	16
Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers	16
MAFLD predicts cardiovascular disease risk better than MASLD	16
Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE)	16
Effects of lifestyle interventions on epigenetic signatures of liver fat: Central randomized controlled trial	15
Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome	15
High prevalence of celiac disease in autoimmune hepatitis: Systematic review and meta‐analysis	15
Real‐life experiences with bulevirtide for the treatment of hepatitis delta—48 weeks data from a German centre	15
The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint	15
Trends in the inpatient burden of alcohol‐related liver disease among women hospitalized in the United States	15
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery	15
Impact of metabolic risk factors on the severity and outcome of patients with alcohol‐associated acute‐on‐chronic liver failure	15
Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO‐C3)	15
Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K/Akt signaling in adult offspring mice	15
Maternal high‐fat diet disrupted one‐carbon metabolism in offspring, contributing to nonalcoholic fatty liver disease	15
The causal effects of inflammatory bowel disease on primary biliary cholangitis: A bidirectional two‐sample Mendelian randomization study	15
EUS‐guided coil and glue injection versus endoscopic glue injection for gastric varices: International multicentre propensity‐matched analysis	15
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C	15
Epidemiology of liver failure in Asia‐Pacific region	15
Associations between alcohol consumption and hepatic steatosis in the USA	15
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study	14
Leukocyte cell‐derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT‐1 pathway in mice	14
The role of macrophage TAM receptor family in the acute‐to‐chronic progression of liver disease: From friend to foe?	14
Epidemic characteristics of alcohol‐related liver disease in Asia from 2000 to 2020: A systematic review and meta‐analysis	14
Diagnosis and management of hepatic encephalopathy: The French recommendations	14
Real‐world effectiveness and safety of direct‐acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study	14
Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus	14
Elastography is unable to exclude cirrhosis after sustained virological response in HCV‐infected patients with advanced chronic liver disease	14
Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination	14
HCV reinfection rates after cure or spontaneous clearance among HIV‐infected and uninfected men who have sex with men	14
Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory	14
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	14
Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three‐arm study	14
Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction–associated fatty liver disease	14
Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis	14
Organophosphate pesticide exposure and biomarkers of liver injury/liver function	14
Extrahepatic manifestations of progressive familial intrahepatic cholestasis syndromes: Presentation of a case series and literature review	14
The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: A systematic review and meta‐analysis	14
Impact of COVID‐19‐related public health measures on HCV testing in British Columbia, Canada: An interrupted time series analysis	14
Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub‐Saharan Africa: Systematic review and meta‐analysis	14
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	14
Update on the management of gastric varices	14
Differential characteristics and outcomes of Asian and non‐Asian patients with HBV‐related hepatocellular carcinoma	14
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab	14